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Abstract
Background: Cerebral small vessel disease is a common cause of vascular cognitive impairment in older people,
with no licensed treatment. Cerebral blood flow is reduced in small vessel disease. Tadalafil is a widely prescribed
phosphodiesterase-5 inhibitor that increases blood flow in other vascular territories. The aim of this trial is to test
the hypothesis that tadalafil increases cerebral blood flow in older people with small vessel disease.
Methods/design: Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS)
is a phase II randomised double-blind crossover trial. In two visits, 7-30 days apart, participants undergo arterial spin
labelling to measure cerebral blood flow and a battery of cognitive tests, pre- and post-dosing with oral tadalafil
(20 mg) or placebo. Sample size: 54 participants are required to detect a 15% increase in cerebral blood flow in
subcortical white matter (p < 0.05, 90% power). Primary outcomes are cerebral blood flow in subcortical white
matter and deep grey nuclei. Secondary outcomes are cortical grey matter cerebral blood flow and performance on
cognitive tests (reaction time, information processing speed, digit span forwards and backwards, semantic fluency).
Discussion: Recruitment started on 4th September 2015 and 36 participants have completed to date (19th April
2017). No serious adverse events have occurred. All participants have been recruited from one centre, St George’s
University Hospitals NHS Foundation Trust.
Trial registration: European Union Clinical Trials Register: EudraCT number 2015-001235-20. Registered on 13 May
2015.
Keywords: Tadalafil, Cerebral blood flow, Vascular cognitive impairment, Vascular dementia, Phosphodiesterase,
MRI, Arterial spin labelling
Background
Cerebral small vessel disease (SVD) is a frequent cause of
vascular cognitive impairment (VCI) in older adults [1–4].
There is currently no licensed treatment for SVD or for
VCI [1, 2]. There is evidence derived from some previous
studies to suggest that cerebral blood flow (CBF) is
reduced in SVD, particularly in subcortical white matter
[5–10]. We hypothesised that increasing CBF has the po-
tential to be both a symptomatic and a disease-modifying
treatment for SVD and VCI.
Phosphodiesterase type 5 inhibitors (PDE5i) such as sil-
denafil and tadalafil are well-established pharmacological
vasodilators that cause enhanced nitric oxide-cyclic
guanosine monophosphate signalling in peripheral small
arteries [11–13]. PDE5i are widely used in treatment of
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erectile dysfunction and pulmonary hypertension [13].
PDE5 messenger RNA and protein are also found in hu-
man brain tissue [12, 14, 15]. Side-effect profiles of PDE5i
are well-known, and the drugs are well-tolerated in the
target population [16–18]. In a meta-analysis of 28
placebo-controlled trials [18], the overall incidence of
myocardial infarction, cardiovascular death or cerebrovas-
cular death in tadalafil-treated patients did not differ from
placebo. The incidence of these adverse events was in-
dependent of dosing regimen and duration of tadalafil
therapy (up to 27 months) [18]. The choice of tadalafil
(over other PDE5i) was based on long plasma half-life
(17 h in healthy adults) [16, 17] and established brain
penetration (brain-to-plasma ratio 1:10 in rodents and
primates) [12, 19]. In this study, we will test whether
single-dose tadalafil increases CBF in older people with
neuroradiological and clinical evidence of SVD.
Methods/design
Objectives
The aim of this study is to test the hypothesis that tada-
lafil increases cerebral blood flow in subcortical areas in
older people with symptomatic SVD.
Study design
Perfusion by Arterial Spin labelling following Single dose
Tadalafil In Small vessel disease (PASTIS) is a phase II
double-blind crossover trial. Participants are randomised
to order of treatment (tadalafil 20 mg, placebo; oral ad-
ministration). Two visits are performed 7–30 days apart,
with perfusion magnetic resonance imaging (MRI) and a
battery of cognitive tests performed before and 3–5 h
after dosing (see Fig. 1).
A Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) checklist is shown in Fig. 2
(see also Additional file 1).
Trial endpoints
The primary endpoints are change in regional CBF in
two sub-cortical brain areas (deep white matter and deep
grey nuclei). The secondary endpoints are (1) change in
regional CBF in cortical grey matter, (2) change in
neuropsychological test performance and (3) plasma
tadalafil concentration dependence of any changes
observed.
Study setting
Participants are recruited from St George’s University
Hospital NHS Foundation Trust and local Participant
Identification Centre sites. All patient visits, data man-
agement and trial coordination are performed at St
George’s. PASTIS has been adopted into the UK Na-
tional Institute for Health Research Clinical Research
Network Portfolio.
Participant characteristics
Participants are older people (men and women) without
a diagnosis of dementia who have radiological and clin-
ical evidence of symptomatic SVD. After informed con-
sent is obtained, the following activities will occur at a
screening visit (see Fig. 1):
1. Trial eligibility criteria check
2. Medical history
3. Concomitant medication checklist: medications,
doses and frequencies
4. MRI suitability/contraindication checklist
5. Participant demographics, including ethnic origin
6. Next-of-kin and general practitioner contact details
to be recorded if not already in medical notes, or
check if still current and up-to-date
7. Affix Clinical Trials Alert sticker to front of the
medical notes
Fig. 1 MOCA Montreal Cognitive Assessment, TOPF Test of
Premorbid Functioning, NIHSS National Institutes of Health Stroke
Scale, MRS Modified Rankin Scale, MRI Magnetic resonance imaging
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8. Complete case report form screening page, ensuring
the participant’s trial identifier is included
9. Test of Premorbid Functioning (TOPF) to establish
estimated levels of cognitive functioning pre-illness
10.National Institutes of Health Stroke Scale (NIHSS)
11.Montreal Cognitive Assessment (MoCA) to establish
estimated levels of cognitive functioning
12.Record the modified Rankin Scale score (mRS)
Inclusion criteria
1. Radiological evidence of cerebral SVD, defined as
MRI evidence of lacunar infarcts (≤1.5 cm
maximum diameter) and/or confluent deep white
matter hyperintensities (WMH) (≥grade 2 on
Fazekas scale)
2. Clinical evidence of SVD, including the following:
a. Lacunar stroke syndrome with symptoms lasting
>24 h, occurring ≥6 months prior to visit 1; or
b. Transient ischaemic attack (TIA) lasting <24 h
with limb weakness, hemi-sensory loss or dys-
arthria ≥6 months previously and with MRI
diffusion-weighted imaging performed acutely
showing lacunar infarction, or, if MRI is not per-
formed within 10 days of TIA, lacunar infarct in
an anatomically appropriate area
3. Age ≥50 years
4. Imaging of the carotid arteries with Doppler
ultrasound, computed tomographic angiography or
Fig. 2 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) checklist: schedule of enrolment, interventions and
assessments in the Perfusion by Arterial Spin labelling following Single dose Tadalafil In Small vessel disease (PASTIS) trial. From PASTIS protocol
version 4, 27 Jan 2016
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magnetic resonance angiography in the previous
12 months demonstrating <70% stenosis in both
internal carotid arteries or <50% stenosis in both
internal carotids if measured in previous 12–60
months
Exclusion criteria
1. Known diagnosis of dementia
2. Cortical infarct (>1.5 cm maximum diameter)
3. Systolic blood pressure (BP) <90 mmHg and/or
diastolic BP <50 mmHg
4. Creatinine clearance <30 ml/minute
5. Severe hepatic impairment
6. History of lactose intolerance
7. Concomitant use of PDE5i (e.g., sildenafil, tadalafil,
vardenafil)
8. Receiving nicorandil or nitrates (e.g., isosorbide
mononitrate, glyceryl trinitrate)
9. Weight >130 kg
10.Uncontrolled cardiac failure
11.Persistent or paroxysmal atrial fibrillation
12.History of gastric ulceration
13.History of ‘sick sinus syndrome’ or other
supraventricular cardiac conduction conditions
14.Uncontrolled chronic obstructive pulmonary disease
15.Stroke or TIA within 6 months
16.MRI not tolerated or contraindicated
17.Known monogenic causes of stroke (e.g., cerebral
autosomal dominant arteriopathy with subcortical
infarcts and leukoencephalopathy)
18.Unable to provide informed consent
Randomisation
The randomisation list will be generated by Sharp Clin-
ical Services (http://www.sharpservices.com/our-facil-
ities/sharp-clinical-services-wales/; Crickhowell, UK)
and will be done in blocks, as detailed in the client study
information form kept in the sponsor site file. The partici-
pants will be acting as their own controls. Each participant
will receive on two separate occasions a placebo dose and
a tadalafil 20-mg immediate dose which appear identical
in size, shape, weight and colour.
The patient pack numbers on the pharmacy shelf correl-
ate directly with the next available pack number on the
blinded randomisation list held in the pharmacy site file.
Each patient pack contains two bottles, labelled as bottle
A and bottle B. The randomisation list will be confidential
to the trial statistician and will be summarised as treat-
ment arm A and B, and not by tadalafil and placebo.
Measurement of regional cerebral blood flow
Whole-brain perfusion will be determined by pseudo-
continuous arterial spin labelling (ASL) [20] in a 3-T
MRI scanner (Achieva TX MRI scanner, Philips Medical
Systems, Eindhoven, Netherlands). A total of 20-minute
pseudo-continuous ASL acquisition time will be used to
provide an adequate signal-to-noise ratio for CBF quan-
tification in white matter. Other image data acquired will
be as follows: an M0 image, to enable quantification of
CBF; high-resolution 3D T1-weighted images for identi-
fication of grey and white matter regions of interest (in-
cluding deep grey matter structures) for ASL analysis
[20] and to map the ASL data to a standard brain atlas;
fluid-attenuated inversion recovery (FLAIR) for delinea-
tion of WMH; and susceptibility-weighted imaging for
detection of micro-haemorrhages. These will provide
participant-specific WMH load and location of WMH.
Total scanning time is under 60 minutes per MRI
session.
Cognitive testing
Scores derived from the TOPF and MoCA instruments
are recorded at the screening visit. These are included in
the analyses as baseline data. They are not used as inclu-
sion or exclusion criteria.
At the two dosing visits, the following neuropsycho-
logical tests are used: the Reaction Time subtest of the
Cambridge Cognition Cambridge Neuropsychological
Test Automated Battery, the Speed of Information Pro-
cessing subtest of the Brain Injury Rehabilitation Trust
Memory and Information Processing Battery, the Digit
Span forwards and backwards subtest of the Repeatable
Battery for the Assessment of Neuropsychological Status
(RBANS), and the Semantic Fluency subtest of RBANS.
Biochemical analyses
A blood sample is taken at the end of visits 1 and 2 for
haematocrit and full blood count analysis. Plasma sam-
ples are stored at −80 °C for subsequent analysis of
plasma tadalafil concentration.
Details of the intervention
Each participant pack contains one bottle containing a
single tadalafil 20-mg capsule and one identical bottle
containing a single matched placebo capsule. At each
visit, participants undergo cognitive tests and the first
MRI scanning session of the day. Participants are then
observed to swallow the appropriate investigational me-
dicinal product (IMP) capsule and receive a standard
light lunch (450–750 kcal and 500 ml of fluid). They
undergo an equivalent, parallel version of the cognitive
tests and the second MRI session of the day 3–5 h later.
All participants are given a 24-h emergency contact card
with the study title, details of the IMP, their participant
trial number, investigator’s contact details, and out-of-
hours contact details (see Fig. 3).
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All those involved in the study (researchers, radiolo-
gists, pharmacists and participants) are blinded to treat-
ment allocation for the duration of the study. Emergency
un-blinding will take place in circumstances such as ser-
ious adverse events (SAEs). Any SAEs and safety end-
points will be reported in line with clinical trial
regulations (SI2004/1031) and the sponsor’s procedures.
We do not anticipate any serious adverse reactions to
the medication, because tadalafil is widely used clinically
and is well-tolerated. The starting point for SAE moni-
toring is the first intervention visit, ending 5 days after
the second visit (based on a drug elimination period of 6
half-lives for the study medication, using a 20-h half-life
for tadalafil).
Power calculation
On the basis of previous ASL studies of regional CBF,
we estimate baseline perfusion of 30 (±10) ml/100 g/mi-
nute (mean ± SD) in subcortical white matter and 70
(±15) ml/100 g/minute in deep grey nuclei [21, 22]. To
detect a treatment effect of 15% (mean paired difference)
with statistical power of 90%, a sample size of 24 is re-
quired in deep grey matter nuclei and 54 in subcortical
white matter. We aim to recruit a target cohort of 54.
Statistical analysis
Baseline characteristics (age, sex, ethnic group, baseline
BP, mRS score, NIHSS, TOPF, MoCA) will be sum-
marised as mean (SD) or median (Q1, Q3) for continu-
ous variables, depending on distribution, and as number
(percent) for categorical variables. Changes in outcome
variables will be calculated for each participant at each
visit as post-dose value minus pre-dose value. Data will
be analysed using a linear mixed effects regression
model with fixed effects for treatment (drug vs. placebo),
visit (visit 1, visit 2), treatment sequence and baseline
response, as well as a random effect for participant
nested within treatment sequence. Carry-over will be
Fig. 3 PASTIS trial emergency 24-hour contact card, supplied to each participant
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investigated by the treatment-by-visit interaction. If sta-
tistically significant, data from each visit will be analysed
separately within linear regression models adjusted for
treatment and pre-dose value. Clinical variables and
other possible confounders (e.g., BP at the time of the
scan) will be included in the linear mixed effects models
as adjustment variables. These will be pre-specified in
the statistical analysis plan.
All analyses will be done on an intention-to-treat
basis, and no adjustment will be made for missing data.
Statistical analyses will be performed using SAS® for
Windows version 9.3 or later software (SAS Institute,
Cary, NC, USA). A p value >0.05 indicates the absence
of a statistically significant effect.
Data monitoring
Monitoring is performed by the sponsor clinical trials
monitor in accordance with an agreed risk-based moni-
toring plan. Case report form entries are verified against
the source documents and the participants’ medical
notes. All data are entered directly from case report
forms to the PASTIS Microsoft Access (Microsoft Corp.,
Redmond, WA, USA) database by the PASTIS research
team. Data transfer from the case report form will be
double-checked, and where corrections are required,
these will carry a full audit trail and justification. Trial
data storage conforms to St George’s institutional infor-
mation governance policies. Trial data, evidence of mon-
itoring and system audits will be made available for
inspection by the sponsor and regulatory authorities as
required.
Discussion
In this randomised, double-blind, crossover phase II
study, we will test whether tadalafil (20 mg) increases
CBF in older people with SVD. Tadalafil was chosen
over other PDE5i (e.g., sildenafil or vardenafil) because
of the documented brain penetration [12, 19] and longer
plasma half-life of tadalafil [16, 17]. In the present trial,
we are simply testing for acute changes in response to a
single dose of tadalafil. For this purpose, a crossover de-
sign appeared optimal. In the event that a positive out-
come is detected in the present study, it appears likely
that a subsequent study testing tadalafil over a longer
dosing period will be required. This will be needed to
explore whether any tadalafil-mediated actions are main-
tained with chronic dosing and to test for any additional
adverse reactions in participants who are likely to be tak-
ing concomitant stroke medications.
ASL was chosen to quantify regional CBF because it
does not require injected radioisotopes or gadolinium
compounds as tracers [20–22]. This MRI-based ap-
proach also enables acquisition of high-resolution 3D
T1-weighted images, T2-weighted FLAIR images and
susceptibility-weighted imaging. The neuropsychological
tests that are used were chosen because each has four
parallel versions of the test to be applied at each screen-
ing point (Fig. 1). The cognitive tests used measure pro-
cessing speed, attention and executive function, which
are affected in SVD, as well as working memory and se-
mantic fluency. Nevertheless, it may be difficult to detect
cognitive changes in such short-term follow-up as is
employed in the present study. The cognitive data ob-
tained from this trial may be of value in assessing sample
size and feasibility for any subsequent trial of tadalafil in
relation to cognitive function.
In addition to the European Union Clinical Trials
Register (EudraCT number 2015-001235-20, date of
registration 13 May 2015), the trial has been registered
with ClinicalTrials.gov (NCT02450253, date of registra-
tion 18 May 2015). No SAEs have been observed so far.
Inadvertent un-blinding due to the erectile effects of
tadalafil has not occurred so far as we are aware. Spon-
taneous penile erection has been reported in a modest
fraction (11%) of subjects taking 20 mg of tadalafil [16,
17]. PASTIS is the first phase II clinical trial of a select-
ive PDE5i in older people with symptomatic SVD. Out-
come data are expected in late 2017 and may inform a
larger trial for re-purposing of tadalafil in SVD and VCI.
Trial status
The trial commenced on 4th September 2015. The PAS-
TIS trial is ongoing. Patient recruitment has not been
completed. As of 19 April 2017, 36 participants have
completed the protocol.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents. (DOC 120 kb)
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